Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

<p>Abstract</p> <p>Background</p> <p>Maintenance therapy with gefitinib notably improves survival in patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutation-positive tumors, but the economic impact of this practice is unclear.</p> <p>Meth...

Full description

Bibliographic Details
Main Authors:	Zhu Jun, Li Te, Wang Xiaohui, Ye Ming, Cai Jian, Xu Yuejuan, Wu Bin
Format:	Article
Language:	English
Published:	BMC 2013-01-01
Series:	BMC Cancer
Subjects:	Gefitinib maintenance treatment EGFR mutation Cost-effectiveness Non-small cell lung cancer
Online Access:	http://www.biomedcentral.com/1471-2407/13/39

Similar Items

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature
by: Wen-Hao Tang, et al.
Published: (2011-09-01)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
by: Wu JY, et al.
Published: (2016-10-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021-08-01)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
by: Alfieri Roberta R, et al.
Published: (2011-11-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
by: Ibrahim Ezzeldin
Published: (2010-01-01)

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
by: Nan Wei, et al.
Published: (2020-08-01)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
by: Jiatao Liao, et al.
Published: (2021-06-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
by: Shen Zhao, et al.
Published: (2020-11-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
by: Lin L, et al.
Published: (2016-10-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
by: Thomas K. Sin, et al.
Published: (2016-02-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
by: Gao W, et al.
Published: (2019-11-01)

Effection and Mechanism of Radiosensitivity of Non-small Cell Lung Cancer Cell Line H358 Following Gefitinib Treatment
by: Jie DENG, et al.
Published: (2011-11-01)

EGFR-TKI plus bevacizumab as maintenance therapy for advanced lung adenocarcinoma: a retrospective study of 192 cases
by: HU Xueting, et al.
Published: (2021-04-01)

Maintenance therapies for non small cell lung cancer
by: Normand eBlais, et al.
Published: (2014-08-01)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
by: Noorwati SUTANDYO, et al.
Published: (2019-09-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01)

Inhibition of EGFR Signaling Protects from Mucormycosis
by: Tonya N. Watkins, et al.
Published: (2018-08-01)

Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
by: Xiaowei Qiu, et al.
Published: (2019-02-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations
by: Joydeb Majumder, et al.
Published: (2021-07-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
by: Ya Gao, et al.
Published: (2018-12-01)

Cannot write session to /tmp/vufind_sessions/sess_5fj5ipeafao9trcfi3efn5mr1o